Lilly Stock Jumps After Phase 3 Weight-Drug Readout
Lilly stock jumps after Phase 3 readout for a next-generation weight-loss drug exceeded expectations. Investors see d...
Glide path describes how a target date fund changes its asset mix as the target year approaches, balancing risk and growth for your retirement.
25,488 articlesLilly stock jumps after Phase 3 readout for a next-generation weight-loss drug exceeded expectations. Investors see d...
A new Fidelity study finds that Americans with a formal retirement plan report higher confidence in their financial f...
Investors are watching Redwire as a multifaceted space tech company. This article explains how redwire's space busine...
As Trump hosts world 80th birthday celebrations, the Strait of Hormuz remains closed and oil trades above $90, fuelin...
A federal judge invalidated the White House’s $100,000 H-1B filing fee, creating immediate uncertainty for U.S. emplo...
In a week-long burst of closings, six starter units priced at $90k-$140k sold, five via seller financing. The episode...
A Flutterwave-led Series E values RLUSD at the heart of Africa's payments network, boosting XRP price prediction pros...
A new milestone for obesity treatment arrives as Novo Nordisk's Wegovy Pill hits 3 million prescriptions. This articl...
A SpaceX IPO could ripple across tech and autos. This guide explains how spacex should help rivian through AI compute...
Two very different tech plays collide in 2026: Innodata edges into AI data preparation, while Workiva anchors large e...
When chip stocks swing, choosing the right side matters. This guide weighs Nvidia vs AMD after the sell-off, with num...
Retail buyers are chasing physical card collectibles tied to crypto platforms, signaling a shift from traditional Tre...